Purine Nucleoside Phosphorylase: A Potential Target for the Development of Drugs to Treat T-Cell- and Apicomplexan Parasite-Mediated Diseases

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|8|3|413-422

ISSN： 1389-4501

Source： Current Drug Targets, Vol.8, Iss.3, 2007-03, pp. : 413-422

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhibitors of the Enzyme Purine Nucleoside Phosphorylase as Potential Therapy for Psoriasis

By  

Current Pharmaceutical Design, Vol. 6, Iss. 9, 2000-06 ,pp. : 943-959

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitors of the enzyme purine nucleoside phosphorylase

By Morris Jr. P.E.   Montgomery J.A.  

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 3, 1998-03 ,pp. : 283-299

Informa Healthcare

Access to resources Recommend Favorite

Transition States and Inhibitors of the Purine Nucleoside Phosphorylase Family

By  

Current Topics in Medicinal Chemistry, Vol. 5, Iss. 13, 2005-10 ,pp. : 1237-1258

Bentham Science Publishers

Access to resources Recommend Favorite

Use of E. coli Purine Nucleoside Phosphorylase in the Treatment of Solid Tumors

By  

Current Pharmaceutical Design, Vol. 23, Iss. 45, 2018-02 ,pp. : 7003-7024

Bentham Science Publishers

Access to resources Recommend Favorite

Epigallocatechin-3-Gallate (EGCG): A Structural Target for the Development of Potential Therapeutic Drugs Against Anti-Proliferative Diseases

By  

Drug Design Reviews - Online, Vol. 2, Iss. 1, 2005-02 ,pp. : 85-91

Bentham Science Publishers

Access to resources Recommend Favorite